Cover Image
Read Now

Disease-modifying drugs for multiple sclerosis final update 1 report

There was no difference in relapse or disease progression between glatiramer and interferon beta-1a SC (Rebif(r)) or interferon beta-1b (Betaseron(r)) based on 2 head-to-head trials. Evidence is insufficient to make any judgments regarding effectiveness in primary progressive or secondary progressiv...

Full description

Bibliographic Details
Main Author: Smith, Beth Paterson
Corporate Authors: Drug Effectiveness Review Project, Oregon Health & Science University Evidence-based Practice Center, Oregon Health & Science University
Format: eBook
Language:English
Published: Portland, Or. Oregon Health & Science University 2010, 2010
Series:Drug class review
Subjects:
Multiple Sclerosis, Relapsing-remitting / Drug Therapy
Antibodies, Monoclonal / Therapeutic Use
Peptides / Therapeutic Use
Disease Progression
Treatment Outcome
Interferon-beta / Therapeutic Use
Antineoplastic Agents / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Table of Contents:
  • Includes bibliographical references

Similar Items